Cargando…

A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective?

Despite community vaccination against coronavirus disease 2019 (COVID-19) and reduced mortality, there are still challenges in treatment options for the disease. Due to the continuous mutation of SARS-CoV-2 virus and the emergence of new strains, diversity in the use of existing antiviral drugs to c...

Descripción completa

Detalles Bibliográficos
Autores principales: Nabi-Afjadi, Mohsen, Mohebi, Fatemeh, Zalpoor, Hamidreza, Aziziyan, Fatemeh, Akbari, Abdullatif, Moradi-Sardareh, Hemen, Bahreini, Elham, Moeini, Amir Mansour, Effatpanah, Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823263/
https://www.ncbi.nlm.nih.gov/pubmed/36609716
http://dx.doi.org/10.1007/s10787-022-01129-1
_version_ 1784866117453348864
author Nabi-Afjadi, Mohsen
Mohebi, Fatemeh
Zalpoor, Hamidreza
Aziziyan, Fatemeh
Akbari, Abdullatif
Moradi-Sardareh, Hemen
Bahreini, Elham
Moeini, Amir Mansour
Effatpanah, Hossein
author_facet Nabi-Afjadi, Mohsen
Mohebi, Fatemeh
Zalpoor, Hamidreza
Aziziyan, Fatemeh
Akbari, Abdullatif
Moradi-Sardareh, Hemen
Bahreini, Elham
Moeini, Amir Mansour
Effatpanah, Hossein
author_sort Nabi-Afjadi, Mohsen
collection PubMed
description Despite community vaccination against coronavirus disease 2019 (COVID-19) and reduced mortality, there are still challenges in treatment options for the disease. Due to the continuous mutation of SARS-CoV-2 virus and the emergence of new strains, diversity in the use of existing antiviral drugs to combat the epidemic has become a crucial therapeutic chance. As a broad-spectrum antiparasitic and antiviral drug, ivermectin has traditionally been used to treat many types of disease, including DNA and RNA viral infections. Even so, based on currently available data, it is still controversial that ivermectin can be used as one of the effective antiviral agents to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or not. The aim of this study was to provide comprehensive information on ivermectin, including its safety and efficacy, as well as its adverse effects in the treatment of COVID-19.
format Online
Article
Text
id pubmed-9823263
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-98232632023-01-09 A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective? Nabi-Afjadi, Mohsen Mohebi, Fatemeh Zalpoor, Hamidreza Aziziyan, Fatemeh Akbari, Abdullatif Moradi-Sardareh, Hemen Bahreini, Elham Moeini, Amir Mansour Effatpanah, Hossein Inflammopharmacology Review Despite community vaccination against coronavirus disease 2019 (COVID-19) and reduced mortality, there are still challenges in treatment options for the disease. Due to the continuous mutation of SARS-CoV-2 virus and the emergence of new strains, diversity in the use of existing antiviral drugs to combat the epidemic has become a crucial therapeutic chance. As a broad-spectrum antiparasitic and antiviral drug, ivermectin has traditionally been used to treat many types of disease, including DNA and RNA viral infections. Even so, based on currently available data, it is still controversial that ivermectin can be used as one of the effective antiviral agents to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or not. The aim of this study was to provide comprehensive information on ivermectin, including its safety and efficacy, as well as its adverse effects in the treatment of COVID-19. Springer International Publishing 2023-01-07 2023 /pmc/articles/PMC9823263/ /pubmed/36609716 http://dx.doi.org/10.1007/s10787-022-01129-1 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review
Nabi-Afjadi, Mohsen
Mohebi, Fatemeh
Zalpoor, Hamidreza
Aziziyan, Fatemeh
Akbari, Abdullatif
Moradi-Sardareh, Hemen
Bahreini, Elham
Moeini, Amir Mansour
Effatpanah, Hossein
A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective?
title A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective?
title_full A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective?
title_fullStr A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective?
title_full_unstemmed A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective?
title_short A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective?
title_sort cellular and molecular biology-based update for ivermectin against covid-19: is it effective or non-effective?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823263/
https://www.ncbi.nlm.nih.gov/pubmed/36609716
http://dx.doi.org/10.1007/s10787-022-01129-1
work_keys_str_mv AT nabiafjadimohsen acellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective
AT mohebifatemeh acellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective
AT zalpoorhamidreza acellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective
AT aziziyanfatemeh acellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective
AT akbariabdullatif acellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective
AT moradisardarehhemen acellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective
AT bahreinielham acellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective
AT moeiniamirmansour acellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective
AT effatpanahhossein acellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective
AT nabiafjadimohsen cellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective
AT mohebifatemeh cellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective
AT zalpoorhamidreza cellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective
AT aziziyanfatemeh cellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective
AT akbariabdullatif cellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective
AT moradisardarehhemen cellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective
AT bahreinielham cellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective
AT moeiniamirmansour cellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective
AT effatpanahhossein cellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective